Low‐dose decitabine plus venetoclax is safe and effective as post‐transplant maintenance therapy for high‐risk acute myeloid leukemia and myelodysplastic syndrome

Acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) are usually associated with poor outcomes, especially in high‐risk AML/MDS. Allogeneic hematopoietic stem cell transplantation (allo‐HSCT) is the only curative option for patients suffering from high‐risk AML/MDS. However, many patients...

Descripción completa

Detalles Bibliográficos
Autores principales: Wei, Yunxiong, Xiong, Xia, Li, Xin, Lu, Wenyi, He, Xiaoyuan, Jin, Xin, Sun, Rui, Lyu, Hairong, Yuan, Ting, Sun, Tongtong, Zhao, Mingfeng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8409404/
https://www.ncbi.nlm.nih.gov/pubmed/34185931
http://dx.doi.org/10.1111/cas.15048

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8409404/
https://www.ncbi.nlm.nih.gov/pubmed/34185931
http://dx.doi.org/10.1111/cas.15048

Ejemplares similares